Seaport Therapeutics Doses First Patient in Phase 2a GlyphAgo Trial
MT newswire2026/10/07 11:2707:27 AM EDT, 10/07/2026 (MT Newswires) -- Seaport Therapeutics (SPTX) said Wednesday that the first patient has been dosed in a phase 2a clinical trial evaluating GlyphAgo in adults with generalized anxiety disorder and sleep disturbance. The six-week trial will evaluate two dose levels of GlyphAgo for their effects on sleep and anxiety symptoms, with topline data expected in early 2028, the company said. The company said phase 1 data showed a statistically significant 6.8-fold increase in bioavailability compared with unmodified agomelatine. Seaport also plans to begin a global phase 2/3 trial of GlyphAgo in GAD in the first half of 2027, with topline data expected by the end of 2028, it added.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Crypto prices
More
